Cadila Healthcare Limited Apixaban Export Data — India (DGFT 2022–2026)

Name: Cadila Healthcare Limited Apixaban Export Records India — #15 Exporter, 23 Shipments, $1.0M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Apixaban

India Pharmaceutical Trade Intelligence

$179.9M171 Suppliers98 CountriesHS 30049099

ExportsIndia → LEBANON41.8%India → CANADA18.3%

ImportsGERMANY → India$14.0B BELGIUM → India$17.4M

Cadila Healthcare Limited — Apixaban Exporter #15 | $1.0M Trade Value | TransData Nexus | TransData Nexus

Cadila Healthcare Limited — Apixaban Exporter Profile

Indian Pharmaceutical Exporter · #15 for Apixaban · $1.0M export value · DGFT Verified

Cadila Healthcare Limited is the #15 Indian exporter of Apixaban with $1.0M in export value and 23 verified shipments. Cadila Healthcare Limited holds a 0.6% market share in Apixaban exports across 5 countries. The company exports 41 pharmaceutical products worth $34.9M across 17 therapeutic categories.

Cadila Healthcare Limited — Apixaban Export Profile: Buyers & Destinations

Cadila Healthcare Limited Apixaban export treemap — buyers and destination countries | TransData Nexus

Where Does Cadila Healthcare Limited Export Apixaban?

Country	Value	Shipments	Share
BRAZIL	$357.9K	8	48.1%
SRI LANKA	$192.9K	8	25.9%
VIETNAM	$115.6K	4	15.5%
URUGUAY	$44.5K	4	6.0%
PHILIPPINES	$32.8K

Who Are the Top Buyers of Apixaban from Cadila Healthcare Limited?

Buyer	Country	Value	Orders
SUNSHINE HEALTHCARE LANKA LIMITED	SRI LANKA	$192.9K	8
BRAINFARMA INDUSTRIA QUIMICA E	BRAZIL	$150.0K	3
ZYDUS NIKKHO FARMACEUTICA LIMITEDA	BRAZIL	$132.9K	3
HAPHARCO J S C BRANCH CHI MINH CITY	VIETNAM	$88.4K	2
BRAINFARMA INDUSTRIA QUIMICA E FARMACEUCTICA SA VPR	BRAZIL	$50.0K	1
LABORATORIO LIBRA S A	URUGUAY	$44.5K	2
ZYDUS HEALTHCARE PHILIPPINES INC	PHILIPPINES	$32.8K	4
ZYDUS NIKKHO FARMACEUTICA LTDA	BRAZIL	$25.0K	1
HAPHARCOJ S CBRANCH	VIETNAM	$22.0K	1
HAPHARCO J S C BRANCH	VIETNAM	$5.1K	1

Cadila Healthcare Limited supplies Apixaban to 11 buyers globally. The largest buyer is SUNSHINE HEALTHCARE LANKA LIMITED (SRI LANKA), followed by BRAINFARMA INDUSTRIA QUIMICA E (BRAZIL) and ZYDUS NIKKHO FARMACEUTICA LIMITEDA (BRAZIL). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.

What Apixaban Formulations Does Cadila Healthcare Limited Export?

Product Description / Formulation	Value	Shipments
THROMBAN 5 Tabs 3x10 Tabs APIXABAN 5 3	$100.0K	2
PHARMA DRUGS & MEDICINE-APIXABAN 5MG TAB	$100.0K	2
APIXABAN 5MG TAB 60S SALE BRAINFARMA 6X	$50.0K	1
APIXABAN 5MG TAB 60 S SALE BRAINFARMA A	$50.0K	1
APIXABAN 5MG TAB 60S SALE BRAINFARMA AP	$50.0K	1
APIXABAN 2.5MG TAB 60S SALE BRAINFARMAAPIXABAN AS PER DOCUMENT	$50.0K	1
APIXABAN TABLETS 5MG APIXABAN TABLETS 5MG 3X10	$50.0K	1
APIXABAN TABLETS 5MG TABS APIXABAN TABLETS 5MG 3X10	$38.5K	1
APIXABAN 5MG TABLET 20s SALE BRAZIL APIXABAN 2X10 QTY-27880.000 PAC-AS PER INV	$32.9K	1
THROMBAN 5 Tabs 3x10 TabsAPIXABAN 53X10 T	$26.6K	1

Cadila Healthcare Limited exports 22 distinct Apixaban formulations including tablets, capsules, syrups, and combination drugs. The top formulation is THROMBAN 5 Tabs 3x10 Tabs APIXABAN 5 3 with 2 shipments worth $100.0K.

How Does Cadila Healthcare Limited Compare to Nearest Apixaban Exporters?

Exporters ranked immediately above and below #15 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
13	TORRENT PHARMACEUTICALS LTD	$1.3M	26	5	$50.0K
10	MSN LABORATORIES PRIVATE LIMITED	$1.1M	23	4	$50.0K
15	CADILA HEALTHCARE LIMITED ★	$1.0M	23	5	$43.9K
14	MACLEODS PHARMACEUTICALS LIMITED	$850.0K	17	2	$50.0K
11	SUN PHARMACEUTICAL INDUSTRIES LIMITED	$750.0K	15	2	$50.0K

Cadila Healthcare Limited ranks #15 among 171 Indian Apixaban exporters. Average shipment value of $43.9K compared to the market average of $497.1K. The closest competitors by value are TORRENT PHARMACEUTICALS LTD and MSN LABORATORIES PRIVATE LIMITED.

Which Indian Ports Ship Apixaban Exports?

Port	Shipments	% Share
SAHAR AIR	724	16.1%
SAHAR AIR CARGO ACC (INBOM4)	674	15.0%
DELHI AIR CARGO ACC (INDEL4)	607	13.5%
DELHI AIR	364	8.1%
MUNDRA SEA	146	3.3%
Bombay Air	134	3.0%
JNPT/ NHAVA SHEVA SEA	131	2.9%
AHEMDABAD AIR ACC (INAMD4)	129	2.9%

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Apixaban Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Zydus. The escalating conflict in the Middle East has disrupted key maritime routes, particularly the Red Sea and Suez Canal, leading to longer transit times and increased freight costs. Major carriers have suspended or restricted transits, extending transit times by 10–20 days and raising freight rates by 40–50% on key India–Europe routes. (livemint.com) This situation poses significant challenges for time-sensitive pharmaceutical shipments, especially temperature-sensitive medicines. (economictimes.indiatimes.com)

Conversely, U.S.–China trade tensions have prompted the U.S. to impose tariffs on Chinese pharmaceutical imports, creating an opportunity for Indian exporters to fill the supply gap. However, the U.S. has also introduced tariffs on Indian imports, including a 25% "reciprocal" tariff, followed by an additional 25% penalty tied to India's continued imports of Russian oil, bringing the total duty to 50%. (en.wikipedia.org) While pharmaceuticals are currently exempt, the potential for future tariffs necessitates strategic planning.

In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial. The FMD mandates stringent serialization and traceability requirements to prevent counterfeit medicines from entering the supply chain. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

Maintaining compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. FDA, WHO, and EU Good Manufacturing Practice (GMP) guidelines set stringent quality benchmarks. Any lapses can lead to import alerts, product recalls, or facility shutdowns. For instance, in 2019, Zydus's Moraiya facility received an Official Action Indicated (OAI) classification from the U.S. FDA, indicating that regulatory and/or administrative actions were recommended. (moneycontrol.com) Such events underscore the importance of robust quality assurance systems.

The evolving regulatory landscape demands continuous investment in compliance infrastructure. The EU's Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act (DSCSA) require advanced serialization and traceability measures. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Apixaban shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Cadila Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 28 individual customs records matching Cadila Healthcare Limited exporting Apixaban, covering 22 formulations to 5 countries via 11 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 98+ countries, 371+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Apixaban

Apixaban

Cadila Healthcare Limited — Apixaban Exporter Profile

Cadila Healthcare Limited — Apixaban Export Profile: Buyers & Destinations

Where Does Cadila Healthcare Limited Export Apixaban?

Who Are the Top Buyers of Apixaban from Cadila Healthcare Limited?

What Is India's Total Apixaban Export Value and How Much Does Cadila Healthcare Limited Contribute?

What Is the Average Shipment Value for Cadila Healthcare Limited's Apixaban Exports?

How Does Cadila Healthcare Limited Compare to Other Indian Apixaban Exporters?

What Apixaban Formulations Does Cadila Healthcare Limited Export?

Regulatory Requirements: Exporting Apixaban to Key Markets

Brazil — ANVISA

How Does Cadila Healthcare Limited Compare to Nearest Apixaban Exporters?

Which Indian Ports Ship Apixaban Exports?

What Other Cardiovascular Products Does Cadila Healthcare Limited Export?

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Apixaban Exports

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

About Cadila Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Apixaban Export Data from Cadila Healthcare Limited

Apixaban Stats

Company Overview

Top Products by Cadila Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source